DTx East 2021

Innes Meldrum is SVP & Chief Commercial Officer at Otsuka Pharmaceuticals USA. Innes leads commercial success of Otsuka’s North American business which includes Neuroscience, Nephrology, and Digital products. Innes oversees Commercial Strategy and Commercial Operations including Market Access, Training and Development, Sales and Marketing Operations, as well as Business Insights and Strategy.

Debra is Founding CEO of Freespira, Inc. and has a history of  CEO and executive positions in medical device and digital therapeutics companies for more than 20 years.  Freespira is an FDA cleared, at-home digital therapeutic that treats panic disorder, panic attacks, and PTSD.  Debra’s expertise includes go-to-market strategies, business modeling, clinical studies, regulatory, reimbursement and fundraising.  Debra is on the board of Digital Therapeutic Alliance (DTA) and is Board Chair for 2021.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Lina Behrens is the Managing Director at Flying Health, the leading ecosystem for Next Generation Healthcare, based in Berlin. She is a Vice President of the German Startup Association and a Member of the Advisory Board „Junge Digitale Wirtschaft“ (Young Digital Economy) of the German Federal Ministry of Economics and Energy. Previously, Lina worked at the Boston Consulting Group (BCG), Social Finance UK and at Polymath Ventures, one of the largest company builders in Latin America. Lina holds an MPA from the London School of Economics and a BA in Economics and in International Affairs from the University of St. Gallen.

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Jennifer Gendron, Chief Commerical Officer at Koa Health, oversees the organizations’ partnerships, client success, sales and marketing in the United States. Gendron brings more than a decade of experience in global health and wellbeing SaaS solutions for employers and health plans. Previous to Koa Health, she served as Head of Development, Innovations for the EX® Program, a digital tobacco cessation solution, and has held leadership positions with Virgin Pulse, MeYou Health, and E4 Health. Gendron’s expertise in high-growth technology is complemented by 10 years of experience as a provider in clinical behavioral health and in behavioral health academia.

Ranjan Sinha founded Digbi Health and serves as the CEO. He is passionate about AI, gut biome and genomics-based precision care and practiced it successfully to address his life-threatening cardio-metabolic disorder. Encouraged by doctor and scientist supporters he decided to commercialize his passion and is now committed to making lifestyle chronic illness optional.

Ranjan has a Master’s degree from The Wharton School and education in engineering and nutrition. He formerly worked at Apple and IBM. He has been an active entrepreneur, starting, building, and leading companies in the areas of large data software, HR software, and services & food.

He is a member of the American College of Lifestyle Medicine, published in leading medical and nutrition journals, an active blogger, and a regular speaker at health and personalized wellness conferences.

Brent Vaughan is CEO of Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease. With more than 20 years of experience, he has a proven track record of success developing proprietary technologies and products across multiple domains, including digital therapeutics, medical devices and pharmaceuticals.

Prior to Cognito, Brent was Chief Executive Officer and Co-Founder at Cognoa, an AI-based digital therapeutics company, where he established the company as a leader in digital therapeutics and pediatric behavioral health. Under his leadership, Cognoa was awarded FDA Breakthrough Designation for the first two products for autism and successfully completed the clinical development of the lead product. He was also co-founder at WellnessFX, a leading digital health company.

Brent has also held leadership positions in business development and product management in therapeutic and medical device companies including Saegis Pharmaceuticals, Nektar Therapeutics, and Roche. He received his M.B.A. from Santa Clara University and a B.S. in Biochemistry from the University of California, Davis.

Adam is Director of Clinical Operations at Curebase, overseeing all Curebase’s clinical trials, including digital therapeutics. Adam has a range of therapeutic and research experience. He began his career as a coordinator and transitioned into monitoring and project management roles of increasing responsibility within CROs, academia, and pharma.

Adam received a master’s in clinical research from George Washington University and is active in his professional community.

Karan Arora currently serves as Chief Commercial Digital Officer, Global Vice President at AstraZeneca.

In his role, he is responsible for leading commercial organizations’ digital evolution. This includes.
1) Next-generation omnichannel capabilities (i.e., advanced analytics, AI/Automation, personalization of experiences) to addresses new go-to-market models and drive commercial upside or operational efficiencies and,
2) Digital health initiatives (i.e., remote monitoring, devices, algorithms) across patients, providers, and payers to drive improved patient outcomes with greater operational efficiencies across the ecosystem.

He has formerly worked at Abbott, Hospira (now Pfizer), Novartis, McKinsey & Company, and Capgemini.

He is actively involved as an angel investor, advising startup teams in the healthcare/technology space, sits on the leadership committee of Chicago life Sciences Consortium, is an Associate/Mentor at CDL-Oxford Said Business School, and a visiting lecturer on digital health at Columbia business school.

He is an industry expert in digital health (speaks at various conferences, published articles), digital marketing (recognized as one of the “40 under 40” leading marketers in the industry by Brand-Innovators in 2015 and 2017), and digital product/services commercialization.

Karan is a visionary leader with P&L experience focused on driving business growth and transformation fueled by Digital, Data, Analytics/AI/machine learning. He is inspired by helping companies innovate & build customer-centric products/solutions, leveraging design thinking & agile delivery. Known as a distinctive people manager & thought partner who enjoys mentoring & motivating teams to deliver exceptional results via analytical/conceptual thinking & problem-solving. Respected by senior executives for a quick grasp of concepts and open, fact-based communication style.

Dr. Keisha Ross graduated from Saint Louis University with a Ph.D. in Clinical Psychology. 

Dr. Ross provides clinical services to children, adolescents, and adults.  Her specialty areas include treating and understanding complex trauma, cultural competence with focus on race/ethnicity with the intersecting identities of religion/spirituality, gender, sexual orientation and disability.  She also is an educator, trainer, clinical supervisor, leader/advocate, consultant and innovator with subject matter expertise in race based stress/trauma. Her research interest includes grants focused improving health communication between providers and racially/ethnically diverse patients and development of culturally sensitive training tools. As Owner/Founder of New Horizon Psychological Services, LLC Dr. Ross provides national and international trainings on diversity, equity, and inclusion; and cultural competence with an emphasis on the impacts of historical/intergenerational trauma on health seeking behaviors among communities of color. She is a member of several local and national organizations holding executive membership and officer positions.  Dr. Ross is recipient of the 2018 Missouri Psychological Association (MOPA) Leadership Award, Inaugural awardee of 2020 St. Louis VA Advancing Diversity in Psychology Award (ADIP), and 2021 ADIP awardee.  She also provides expert testimony with an emphasis on the impacts of structural racism, implicit bias, and historical/intergenerational trauma as it relates to the intersection of mental health and criminal justice system and its influence on offending behaviors.  Her passion is in decreasing stigma about mental health with focus on advocacy/empowerment in urban minority areas and underserved populations.  

Kathryn is a Sales Director with a focus on population health.
A former clinician, she has a heart for both patients and providers. With her firsthand knowledge of the
healthcare industry, Kathryn enjoys presenting creative solutions that can improve patient outcomes
and reduce financial risk.
In the past, Kathryn has held positions in business development with Sound Physicians, the Orthopedic
and Sports Therapy Institute, and Kindred Healthcare. She started her career with Johnson & Johnson as
a cardiovascular specialty representative.
She is also an Adjunct Professor at OSF Saint Anthony College of Nursing, teaching courses in both
graduate and doctoral programs.
Besides a Masters degree in Business and Management, Kathryn holds a Doctorate in Health Science
with a focus on population health.

Kamal is an industry leader with 15+ years of experience in digital health from a provider
perspective, most recently at MassGeneral Brigham, with background in digital health strategy,
product design and clinical research and validation. Kamal has developed and implemented
100+ digital health programs and is widely published in the value digital health can bring to
healthcare delivery.

Jaydev Thakkar, Chief Operating Officer of Biofourmis, has over 25 years’ experience in leadership roles in the world’s leading pharma and biotech organizations, from Fortune 100 powerhouses to groundbreaking startups, where he boasts an accomplished record of sparking technology innovations; forming strategic alliances; and leading global IT, software engineering, and architecture teams. At Biofourmis, Thakkar leads the strategy and execution of Biofourmis’ digital therapeutics pipeline and running its clinical research operations, manufacturing operations and supply chain aspects. In his most recent role prior to Biofourmis, Thakkar served as director of Digital Health and Innovation at Amgen for 14 years, where he led its “beyond the therapy” digital innovation strategy to maximize product value and clinical outcomes across the patient journey

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Eddie frequently serves on discussion panels for industry and academic events related to healthcare innovation, has appeared in media including CNN’s Vital Signs with Sanjay Gupta, and Akili has received recognition including the 2014 Future of Health Technology product award, 2015 50-on-Fire Boston, and the #1 health company in Entrepreneur magazine’s 100 Brilliant Companies of 2016.

Valerie Sullivan brings significant experience in the pharma, digital health and pharma services industries to her previous role as President and CEO of etectRx. Innovative and forward thinking, she is passionate about creating meaningful, cost-effective solutions across the healthcare ecosystem by leveraging patient engagement and digital technology to support greater outcomes, more therapeutic impact and the potential to serve an unmet need.Prior to joining etectRx, she served as President of InVentiv Patient Access Solutions, a tech-enabled patient support services company. In addition, she served as Vice President and General Manager of the Patient Service Center at Pear Therapeutics, a program that she envisioned and built from the ground up. She began her career in healthcare working at Pfizer for over 15 years. Sullivan serves as an independent member on the board of directors at CareMetx and Two Labs Pharma Services, and is Chairman at the Group Insurance Commission, a quasi-state agency in the Commonwealth of MA. She is on faculty at Bentley University as an adjunct professor in the Management Department. She holds a Bachelor of Arts in Chemistry and Economics from College of the Holy Cross and an MBA in Finance and Marketing from Northeastern University.

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

Mette Dyhrberg is a digital health innovator committed to improving the quality of life for those with chronic disease. She is the founder and CEO of Mymee, a digital program that is rethinking autoimmunity. The Mymee protocol eases the symptoms of autoimmune disease through data analytics and health coaching.  As an authority on autoimmune issues, Mette is a frequent speaker at industry events and conferences such as Stanford Medicine X and Exponential Medicine.

Mette holds MS in economics and is a certified health coach. An economist turned diagnostician, she’s the Sherlock Holmes of anamnestic data. She first entered the functional medicine arena in an attempt to tackle her own chronic health issues. In her early twenties, she became severely ill. For years, Mette battled an ever-expanding array of medical diagnoses ending up with six different autoimmune diseases simultaneously. Mette took matters into her own hands, hacked her own health and in doing so, she created a tool that solved her health problems and soon began helping others do the same.

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-evaluated digital therapeutics into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Amir is an established neuroscientist specialized in digital medicine and clinical innovation. His strategic vision is empowered by real-world data that enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. He brings an entrepreneurial zeal to the clinical world through disruptive technology and AI analytics from proof of concepts to scale-up solutions. Prior to pharma , Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health and served as a PI on numerous clinical trials with 200+ publications and conference presentations.

Laura Yecies is the CEO of Bone Health Technologies, maker of OsteoBoost, the first effective and safe non-drug treatment for low bone density.  Previously she was CEO of SyncThink a medical diagnostic company, Catch, which she sold to Apple and SugarSync which was acquired by J2Global.  Earlier she led the Browser division at Netscape, was general manager of Yahoo Mail and VP of Marketing at Check Point.  Ms. Yecies has led commercialization and product development programs that have resulted in the use by over 350m customers.  She received her MBA from Harvard, has an MSFS from Georgetown and her AB in Government Magna Cum Laude from Dartmouth.   She has been profiled in the NYTimes and multiple periodicals and is a prolific speaker and writer on health care and technology. 

2012 Stevie Awards for Women in Business — Silver Medal for Female Executive of the Year.

Inc. 500 — Top Female CEO of 2012 

U.S. Department of State TechWomen Mentor.

2011 Stevie Awards for Women in Business — Gold Medal for Female Executive of the Year

Dr. Liz Kwo is an experienced healthcare executive with 15+ years specialized in building and scaling digital healthcare products to provide high quality care, leveraging predictive and prescriptive analytics to improve outcomes. Her current role at Anthem is to create digitized, automated, and continuously improved frictionless patient and provider experience that drives down cost of care. She has worked in remote patient monitoring for Medtronic, American Well as the VP of Provider Networks for telehealth, and is an active angel investor in the healthcare community, with a specific interest in technology-enabled healthcare delivery such as RubiconMD. She founded multiple venture-backed companies in educational technology (sold to CVC private equity firm in 2014), digital healthcare, and healthcare supplies and is passionate about creating seamless tailored experiences for enrolling patients and building on-demand data driven insights to support national employer clients.

Dr. Kwo has extensive experience in healthcare technology product development and commercialization, P&L, B2B/B2C marketing & sales, strategic partnerships, & post-merger integration. A practicing physician in urgent and preventive care, Dr. Kwo’s clinical expertise allows her to translate ideas from bench to bedside. She is also a lecturer in the Harvard-MIT HST Program and an Instructor of Medicine at Harvard Medical School.

Dr. Kwo has an MD from Harvard Medical School, MBA from Harvard Business School, MPH from Harvard TH Chan School of Public Health, and a BA from Stanford University. She completed her residency at Harvard Preventive Care and is Board Certified in Preventive Care and Occupational Medicine.

Melinda Decker is Chief Commercial Officer of Mymee, the leading provider of 100% remote, digital care programs designed to help people with autoimmune disease reclaim their health. Mymee’s commercially validated trigger identification platform combines mobile technology, data analytics and personalized coaching to find the unique diet and environmental triggers behind each person’s disease symptoms and guide meaningful improvements in quality of life. Mymee currently offers it’s program directly to individuals, as well as through large self-insured employers and health plans.

Melinda also serves as an advisor to MIT’s Health Science & Technology program and to several companies focused on digital health. She previously held leadership roles at AstraZeneca and Pfizer, spanning commercial and R&D.  Melinda holds an MS in Biochemical Engineering and an MBA in Finance and Marketing.

Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas.  Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business.  In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device.  Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business.  She received an MSc from Waseda University and an MBA from Tsukuba University.

Ian Marcus is Team Lead for the Digital Health Policy Leadership and Development Team in FDA’s Digital Health Center of Excellence (DHCoE), Center for Devices and Radiological Health (CDRH). In this role, he leads the development and implementation of new policies and guidance documents, helps stakeholders navigate the regulatory landscape for novel and complex digital health technologies and innovations, and develops new regulatory approaches to address the unique considerations these technologies raise.

Ian began his FDA career in 2015 as a Biomedical Engineer and Lead Reviewer in the Office of Neurological and Physical Medicine Devices, leading interdisciplinary teams to review more than 200 pre- and post-market medical device submissions that covered a range of novel technologies, including wearables, mobile apps, electrical stimulators, exoskeletons, and brain computer interfaces.

Before joining the FDA, Ian worked as a Research Engineer at the Center for Injury Biomechanics at the Wake Forest School of Medicine. He received his bachelor’s degree in Engineering Science and Mechanics with a Biomechanics Focus from Virginia Tech in 2013 and received his master’s degree in Engineering Mechanics from Virginia Tech in 2014.

Dr. Dixit is a Physician Executive with more than 20 years of experience in the healthcare and life sciences industry. She has been in executive leadership at Sanofi, Allergan, and GE and has been responsible for launching a number of innovative medicines. She was voted innovator of the year at GE in 2008, nominated as a Top 50 Thought Leader in “Big Data” in Life Sciences in 2016, and featured in the Pharma Executive Magazine cover-page article “Real-World Evidence: From Volume to Value” (Oct 13, 2016). Shailja has built and has had successful exits with many projects.

David Kiger is GVP for Biofourmis Therapeutics team where he leads go-to-market strategy and sales. He previously worked as CCO for other digital health companies such as Datacubed Health and Bioclinica overseeing global sales teams, corporate marketing, and solutions. David worked 16 years at PAREXEL Informatics and was VP of Product Strategy where he helped launch all offerings across patient, clinical, and regulatory technologies. David brings a diversified career of 25+ years of experience in product and digital marketing, product management, alliances, business development, and management consulting.

Meg is passionate about driving change by collaborating with physicians, technology leaders and solution innovators to improve health care. She has served in product development and business development leadership roles at the AMA and most recently is responsible for driving the roadmap of initiatives that support the AMA’s digital health and medicine strategy. In addition, she has led partnerships and innovation related initiatives, such as the inaugural AMA Healthier Nation Innovation Challenge, the establishment of the AMA Interaction Studio at MATTER, the AMA Physician Innovation Network that enables entrepreneurs and physicians to collaborate on the development of new solutions, the AMA Digital Health & Telehealth Implementation Playbook series, AMA Digital Health research and The Telehealth Initiative with collaborators. She participates on the Advisory Board for MATTER, MassChallenge HealthTech, HealthTech Arkansas, Together.Health and as a TEDMed Research Scholar. She also participates on the Editorial Review Board of The Telehealth and Medicine Today Journal.

Meg has spoken at national conferences such as Health 2.0, Connected Health, HLTH, American Telemedicine Association National Conference, AMA State Advocacy Conference and contributes as speaking faculty for Columbia Business School’s Digital Health program curriculum. She has articles published in Health Affairs, Harvard Business Review and Nature Digital Medicine.

Prior to AMA, Meg worked in the Consumer Product & Retail vertical at Capgemini and at SmithBucklin Corporation for various business and health care clients.

Kimberly Tableman is Chief Clinical Development Officer (CCDO) at Castor. She has more than 23 years of experience in clinical development and technology. Over the past decade, she has focused on applying digital health technologies to reimagine the patient journey. She was most recently CEO at Medicine X, and co-founder at Rabble Health, where she led the development and beta launch of a patient engagement platform to serve oncology patients. Prior to Medicine X, Kimberly held senior roles at GlaxoSmithKline (GSK), including Head of Patient Engagement and Head of Digital Clinical Trials. She has also worked at Pfizer, and began her career in management consulting at Cap Gemini Ernst & Young.

Dr. Offidani is the Associate Director of Medical Affairs at Click Therapeutics. She received her PhD in Clinical Psychology from the University of Bologna (Italy) and has more than 10 years of experience working in clinical research in higher education and industry. She is a trained clinical epidemiologist with extensive experience in designing and implementing studies using CROs, PROs and EHR data. She holds an appointment as Adjunct Assistant Professor of Clinical Epidemiology Research in Medicine at Weill Cornell Medicine. She authored and co-authored 30+ scientific articles and book chapters.

Julia Strandberg serves as Chief Commercial Officer at Pear Therapeutics, responsible for crafting and implementing patient-, clinician-, and payer-centered strategies to accelerate the adoption of Prescription Digital Therapeutics (PDTs). She draws on extensive experience in developing and commercializing innovative medical technologies. From medical devices and RFID technologies, to consumer electronics, she has championed novel technologies and innovative business models to transform healthcare and advance the healthcare industry.

Prior to joining Pear, Julia served as Medtronic’s Vice President & General Manager for the Health Informatics & Monitoring division. She also has served as Vice President of Global Marketing for the Patient Monitoring franchise for Covidien. Julia joined Covidien in the Strategy & Portfolio group for Sleep Diagnostics and Therapy. She began her career at 3M Company, where she held multiple engineering and marketing positions in the Optical Systems and Track and Trace solutions division.

She earned her MBA from University of Minnesota, Carlson School of Management, and her undergraduate degree in Chemical Engineering at Purdue University.

Adam serves as the Managing Director at Dreamit Ventures, a Philadelphia based venture fund and catalyst, where he leads the HealthTech vertical. Dreamit focuses on late Seed and Series A ready digital health and medtech startups. Adam’s career has focused on building early stage venture-backed companies. He co-founded five health technology companies and served as CEO of three.  He has raised significant venture capital and led several M&A transactions. Adam serves on the boards of Safkan Health, RightAir, and ZSX Medical and is an active angel investor. He is a named inventor on eight U.S. patents. He teaches a graduate level course on entrepreneurship within the Penn School of Medicine. Adam holds a BSE from the Wharton School and an MBA from UCLA.

Dr. Andrey Ostrovsky is an investor, senior operating leader, and health policy expert with over a decade of experience applying human-centered design, agile development, lean management, quality improvement, and entrepreneurial principles to eliminate disparities and sustainably achieve the Quadruple Aim.

He has proven leadership experience setting growth strategy and translating research into practice for early stage technology startups, growth stage services companies, and regulatory organizations.

Dr. Ostrovsky’s health expertise includes population health, value-based payment, social determinants of health (SDOH), quality measurement, care coordination, home and community-based services (HCBS), pediatrics, and behavioral health. He is a board-certified and practicing physician.

Kuldeep Singh Rajput is the CEO and Founder of Boston-based Biofourmis, a fast-growing global leader
in digital therapeutics that powers personalized predictive care. Biofourmis’ wearable sensor, remote
monitoring and artificial intelligence-based predictive analytics are used to improve outcomes and lower
costs in various therapeutic areas, including heart failure, oncology, pain, and most recently infectious
disease–specifically for COVID-19 monitoring. Biofourmis is pioneering an entirely new category of
digital health, with its clinically validated software-based therapeutics and wearables platform that
provide better outcomes for patients, smarter engagement and tracking tools for clinicians, technology
to complement and demonstrate the value of pharmacotherapy, and cost-effective solutions for payers.
The company’s technology has also been used in FDA-funded clinical research focused on speeding drug
development times to decrease costs and get drugs to market more quickly. Recognized as a “Forbes 30
Under 30,” Rajput has demonstrated strong leadership experience with building teams, developing
talent, and successfully growing and managing strategic partnerships with global pharmaceutical
manufacturers, health systems and payers. Under his leadership, Biofourmis has raised over $145
Million in venture capital from leading Venture Capital firms including Sequoia Capital, MassMutual
Ventures, Aviva plc, and Mayo Clinic Ventures.

Eric Buffkin is the CEO and President of etectRx, a digital health company. Eric is a repeat
entrepreneur and executive with more than 25 years of experience launching tech and health-tech
ventures. As a co-founder of the company, he has a long-standing commitment to etectRx values, digital
pill technology and the market potential for the ID-Cap™ System. Eric continues to set the direction for
etectRx technology, creating meaningful conversations with target collaborators on improving health
data and creating unequivocal medication ingestion records.

Eric was previously the Senior Vice President of Development and Technical Operations for etectRx and
led the team to FDA clearance for the ID-Cap System in December 2019. Outside of etectRx, Eric
founded the Pelagic Group, an active consulting firm focused on advising STEM startups. He is also
currently a mentor at the University of Florida and Carnegie Melon, providing advice and counsel in
innovation and entrepreneurship accelerator programs. He has served in executive roles with Intellon
Corporation and Motorola earlier in his career. Eric has a Master of Business Administration from Rollins
College and a Bachelor of Science in Electrical Engineering from the University of Florida. He holds three
active US and International patents and multiple pending patients.